Patients with eosinophilic granulomatosis with polyangiitis experienced significant improvements in a variety of outcomes ...

Patients with eosinophilic esophagitis in the US have high health care resource utilization costs, according to a retrospective national claims study.

Researchers conducted an international phase 2 multicenter trial to assess the efficacy and safety of etrasimod vs placebo in patients (age, 18-65 years) with previously diagnosed and ...

VICTORIA, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia” or the "Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its ...

VICTORIA, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical ...

NS-229 is currently being evaluated in a phase 2 trial in patients with eosinophilic granulomatosis with polyangiitis. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...

The best eosin Y removal percentage had 87.7% in 25 g L-1 of peanut ... The dried PS was grinded by blender machine to fine powder, then PS powder was sieved through to 2 mm diameter and stored in ...

A Prescription Drug User Fee Act target date of December 16, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License ...

VICTORIA, BC, Feb. 25, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...

In a prior phase 2 study, cendakimab, which selectively binds to IL-13 and blocks its interaction with both the IL-13Ra1 and the IL-13Ra2 receptors, was shown to improve symptoms and endoscopic ...